Pulmatrix, Inc. (PULM)
PULM Stock Price Chart
Explore Pulmatrix, Inc. interactive price chart. Choose custom timeframes to analyze PULM price movements and trends.
PULM Company Profile
Discover essential business fundamentals and corporate details for Pulmatrix, Inc. (PULM) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
21 Mar 2014
Employees
2.00
Website
https://www.pulmatrix.comCEO
Peter Ludlum CMA, MBA
Description
Pulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing Pulmazole, an inhaled anti-fungal drug for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma, and in patients with cystic fibrosis; PUR1800, a narrow spectrum kinase inhibitor that is in Phase 1b clinical trials for patients with stable moderate-severe chronic obstructive pulmonary disease; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine. The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of Pulmazole; and a collaboration and license agreement with Sensory Cloud, Inc. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.
PULM Financial Timeline
Browse a chronological timeline of Pulmatrix, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 May 2026
Upcoming earnings on 6 Nov 2025
Earnings released on 6 Aug 2025
EPS came in at -$0.42 .
Earnings released on 15 May 2025
EPS came in at -$0.50 .
Earnings released on 21 Mar 2025
EPS came in at -$0.54 , while revenue for the quarter reached $3.00K .
Earnings released on 8 Nov 2024
EPS came in at -$0.71 , while revenue for the quarter reached $366.00K .
Earnings released on 13 Aug 2024
EPS came in at -$0.87 , while revenue for the quarter reached $1.55M , missing expectations by -29.52%.
Earnings released on 10 May 2024
EPS came in at $0.23 , while revenue for the quarter reached $5.89M , beating expectations by +167.26%.
Earnings released on 28 Mar 2024
EPS came in at -$0.57 surpassing the estimated -$1.04 by +45.19%, while revenue for the quarter reached $2.20M , beating expectations by +24.41%.
Earnings released on 9 Nov 2023
EPS came in at -$1.03 surpassing the estimated -$1.05 by +1.90%, while revenue for the quarter reached $1.75M , missing expectations by -0.96%.
Earnings released on 10 Aug 2023
EPS came in at -$1.04 surpassing the estimated -$1.23 by +15.45%, while revenue for the quarter reached $1.84M , beating expectations by +21.80%.
Earnings released on 12 May 2023
EPS came in at -$1.22 , while revenue for the quarter reached $1.50M .
Earnings released on 30 Mar 2023
EPS came in at -$1.14 surpassing the estimated -$1.44 by +20.83%, while revenue for the quarter reached $1.71M , missing expectations by -8.66%.
Earnings released on 10 Nov 2022
EPS came in at -$1.45 surpassing the estimated -$1.51 by +3.97%, while revenue for the quarter reached $1.87M , beating expectations by +61.38%.
Earnings released on 8 Aug 2022
EPS came in at -$1.36 surpassing the estimated -$1.51 by +9.93%, while revenue for the quarter reached $1.33M , beating expectations by +14.74%.
Earnings released on 12 May 2022
EPS came in at -$1.51 falling short of the estimated -$1.41 by -7.09%, while revenue for the quarter reached $1.16M , beating expectations by +8.51%.
Earnings released on 29 Mar 2022
EPS came in at -$2.43 falling short of the estimated -$1.60 by -51.88%, while revenue for the quarter reached $456.00K , missing expectations by -61.22%.
Stock split effective on 1 Mar 2022
Shares were split 1 : 20 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 10 Nov 2021
EPS came in at -$1.80 falling short of the estimated -$1.40 by -28.57%, while revenue for the quarter reached $1.07M , beating expectations by +40.00%.
Earnings released on 10 Aug 2021
EPS came in at -$1.40 surpassing the estimated -$1.80 by +22.22%, while revenue for the quarter reached $2.25M , missing expectations by -18.18%.
Earnings released on 11 May 2021
EPS came in at -$1.80 surpassing the estimated -$2.00 by +10.00%, while revenue for the quarter reached $1.39M , missing expectations by -9.09%.
Earnings released on 23 Mar 2021
EPS came in at -$1.00 surpassing the estimated -$3.80 by +73.68%, while revenue for the quarter reached $2.00M .
Earnings released on 12 Nov 2020
EPS came in at -$6.20 falling short of the estimated -$4.40 by -40.91%, while revenue for the quarter reached $4.37M , beating expectations by +53.85%.
PULM Stock Performance
Access detailed PULM performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.